• Home
  • 2.0 LPBI Executive Summary
  • 1.0 LPBI Executive Summary
  • Journal PharmaceuticalIntelligence.com
  • Portfolio of IP Assets
  • Knowledge PORTALS System (KPS)
  • 1.0 LPBI – 2012-2020 VISTA
  • LPBI Group’s History
  • 2.0 LPBI – 2021-2025 VISION
  • BioMed e-Series
  • Press Coverage
  • Investor Relations
  • Our TEAM
  • Founder
  • Funding, Deals & Partnerships
  • 1.0 LPBI Group News
  • 1.0 LPBI CALENDAR
  • 2.0 LPBI Group News
  • Testimonials about LPBI
  • DrugDiscovery @LPBI Group
  • Medical 3D Printing
  • e-VOICES Podcasting
  • LPBI Newsletters
  • Customer Surveys
  • Health Care INVESTOR’s Corner ($)
  • 2021 Summer Internship Portal
  • 2021-2022 Medical Text Analysis (NLP)
  • Artificial Intelligence: Genomics & Cancer
  • SOP Web STAT
  • Blockchain Transactions Network Ecosystem
  • Contact Us
  • 1.0 LPBI Brochure
  • 2.0 LPBI Brochure
  • 2.0 LPBI – Calendar of Zooms
  • Coronavirus, SARS-CoV-2 Portal
  • LPBI India
  • Synthetic Biology in Drug Discovery
  • Certificate One Year
  • NFT: Redefined Format of IP Assets
  • Audio English-Spanish: BioMed e-Series
  • Five Bilingual BioMed e-Series

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Funding, Deals & Partnerships: BIOLOGICS & MEDICAL DEVICES; BioMed e-Series; Medicine and Life Sciences Scientific Journal – http://PharmaceuticalIntelligence.com

Feeds:
Posts
Comments

Voices from the Coronavirus Pandemic in China

5/22/2020

China’s Broken Healthcare System

Reporter: Gail S. Thornton, M.A.

The following article is reprinted from Time magazine.

How the Coronavirus Is Helping to Fix China’s Broken Healthcare System

A respiratory and critical care medicine department doctor communicates with patients via Tianjin Medical University General Internet Hospital's platform on March 4, 2020 in Tianjin, China.

A respiratory and critical care medicine department doctor communicates with patients via Tianjin Medical University General Internet Hospital’s platform on March 4, 2020 in Tianjin, China.
Tong Yu/China News Service via Getty Images
BY CHARLIE CAMPBELL / SHANGHAI 
MAY 6, 2020 12:20 AM EDT

When Dai Yufan began developing a fever and painful cyst, her first thought was to see a doctor. But due to the COVID-19 pandemic, visiting her local hospital seemed scarier than her symptoms.

“So I tried an online health service,” says Dai, 27, an office worker in the southern Chinese city of Shenzhen. “I asked about my condition via an app and [a doctor online] suggested some medicine and other treatments.”

While the coronavirus has stretched medical services around the world to breaking point, the virus has also fostered a boom in online medical services, known as telehealth. The industry is predicted to be worth almost $30 billion this year in China alone and has the potential to transform Chinese healthcare by reducing strain on urban hospitals and providing a stop-gap solution for rural dwellers.

China already has over 1,000 telehealth companies, according to data firm Tianyancha, including some run by tech giants JD.com, Baidu, Tencent and Alibaba. Dai used the Good Doctor subsidiary of Ping An Insurance, which claimed in September to have 300 million registered users. All are seeing a boom in consultations due to lockdown measures.

Before the pandemic, JD Health took 10,000 online consultations per day. But as hospitals and clinics became swamped with suspected coronavirus patients, that has rocketed to 150,000, with JD Health’s own pharmacy delivering medicines directly to patients’ homes. Xin Lijun, CEO of the $7 billion-valued company, says the convenience of telehealth will remain attractive after the crisis abates.

“People have developed the habit of getting diagnosis and treatment online,” Xin tells TIME. “This greatly reduces the pressure on traditional hospitals.”

China’s healthcare system has made vast strides over the past few decades. Public sector spending on health care increased almost 14-fold between the SARS outbreak in 2003 and the end of 2018, according a March 2019 report by the WHO and World Bank. Nearly every Chinese citizen has some level of health insurance, with patients contributing an average of 32% of their treatment costs compared with 60% a decade ago.

But problems persist, especially as a severely aging population increases demand for treating chronic conditions such as arthritis, cancer and heart disease. China has only 1.8 doctors for every 1,000 people, compared with 2.4 in the U.S. and 2.8 in the U.K. Compounding matters, China’s doctors are unevenly weighted towards specialties to the detriment of primary care.

While the U.S. has a dozen family doctors for every 10,000 citizens, China has just 2.2, meaning specialists at Chinese hospitals are overburdened with general duties. Chinese patients typically queue up for many hours at highly ranked hospitals even for minor aliments but remain suspicious of underutilized local clinics. According to the WHO and World Bank report, China’s healthcare is too “hospital-centric, fragmented, and volume driven.” The system is also becoming too expensive to sustain, with healthcare costs growing 5-10% faster than GDP.

Online consultancies can help solve many of these issues, explaining why so many companies are aggressively exploring the space. Baidu Health boasts over 100,000 doctors from across China who offer online consultations 24 hours a day. The platform was made free to those with pneumonia symptoms during the pandemic and had handled over 54.5 million enquiries by Apr. 26, including 400,000 from outside China.

It’s also a boon for China’s overworked and underpaid doctors, who are able to supplement their income via online services. Dr. Qiao Guibin, director of Thoracic Surgery at Guangdong Provincial People’s Hospital, works for Baidu Health part-time. By encouraging patients to stay at home during the pandemic, online healthcare also reduces the chances of cross-infection of both patients and doctors.

“Online medical treatment may have saved a lot of lives during the pandemic,” says Qiao.

And not just in China. Qiao even treated a patient in Canada who had contracted COVID-19. “He was very anxious at first,” say Qiao. “But I reassured him that as a young man he shouldn’t worry too much, because 80% of people do not need medicine and COVID-19 [as a viral disease] is self-healing.”

Qiao checked in with the patient daily during his quarantine and heard a few days ago that he had completely recovered. “He is very grateful.”
There are also mental health benefits for patients isolated from friends and family due to lockdown measures. When Cai Anqi, 23, a public health student in London, developed a fever she naturally worried it might be COVID-19. However, the U.K. government’s guidelines were simply to self-quarantine unless her symptoms severely worsened. Wracked with worry, she instead turned to China’s telehealth provider WeDoctor.

“I described my condition: fever, dizziness, and runny nose, but without a cough. The doctor’s advice was to rest more, eat nutritious food, drink more water. She said as long as I don’t cough, it should be fine, as a cough is the main symptom of COVID-19. After her professional advice, I didn’t panic so much. After a few days following the doctor’s advice, the fever was gone.”

The U.S. is also trying to boost the sector in response to the pandemic. In March, President Trump advocated waiving certain federal rules to allow doctors to provide care remotely using video chats and other services. “What they’ve done with telehealth is incredible,” Trump said.

Across the U.S., telehealth provider Amwell has seen an increase in patient volumes of around 150-300% generally and up 700% during the early days of the outbreak in Washington State. Some individual hospitals have increased demand for Amwell’s services 20-fold in an effort to shield front line medical workers. Amwell CEO Roy Schoenberg says telehealth has proved particularly valuable in “geographic care deserts” and for elderly patients with mobility issues.

“We see this application of the technology as critical for democratizing healthcare and ensuring that all in need of care can access it, during COVID-19 and in the future,” he tells TIME.

Telehealth also allows patients to choose doctors based on their experience and patient reviews. Dr. Liu Yafeng has 18 years’ experience working as a gastroenterologist in China’s Hebei province, where he also ran the local hospital’s oncology and ICU departments. But while he might handle 30 consultations a day at a bricks and mortar hospital, he can manage about 200 online. It cost just 10 renminbi ($1.40) for an online consultations via JD Health or 15 renminbi ($2.10) for a 15 minute voice consultation. Liu has made 15,154 online diagnoses since joining the firm, with a 99% patient satisfaction rate.

“I get a greater sense of accomplishment because of all the positive feedback I receive from patients,” he says.

Still, significant challenges remain: “The biggest challenge of telehealth comes from diagnosis, which often requires specialist equipment,” says Liu. “It is an emerging industry and may take a long time to solve this problem.”

The concerns are echoed by the patient, Dai.

“I will still use the online health service after the pandemic, but I don’t think I trust online doctors’ diagnosis quite as much as a proper consultation,” she says. “I still feel distant from the online doctor. After all, he doesn’t know all my problems.”

—With reporting by Zhang Chi/Beijing

SOURCE:

https://time.com/5832584/coronavirus-covid19-telehealth-online-healthcare/

###

4/25/2020

Opinion Articles from the Lancet: COVID-19 and Cancer Care in China and Africa

Reporter: Stephen J. Williams, PhD

https://pharmaceuticalintelligence.com/2020/04/25/opinion-articles-from-the-lancet-covid-19-and-cancer-care-in-china-and-africa/

3/28/2020

Ambassador to China talks about life under quarantine in Beijing

“It’s not a total return to routine yet,” the ambassador said. “When I look at the streets, it’s not the Beijing I know; no schools and universities, not all the restaurants are open, and people are sitting far from each other. But the decisiveness of the government was great, and they finished with this ordeal in two months. People are still concerned and stay home when they can.”

The Chinese government “wouldn’t take another chance. They’re very careful with opening Wuhan,” he added.

“Now Chinese people are afraid of catching the coronavirus from the world; it’s come full circle,” he said.

Heifetz has been working on bringing supplies to Israel from China, and to that end met with Alibaba founder and billionaire Jack Ma, whom he called a friend of Israel. Ma donated tens of thousands of masks, coronavirus tests and items of protective clothing to Israel.

Heifetz also said he thinks it’s “unfair” for the world to make demands on China – for example, by demanding more hygienic conditions in the “wet” wildlife markets that were the source of the 2002-2003 SARS outbreak and that were, many epidemiologists say, are the source of the current outbreak.

“There have been outbreaks of diseases in Europe and Africa and other places in the world. To hold China to account because it happened by them and not somewhere else is so unfair, because I think the war they waged against this disease is not just their personal war,” Heifetz argued.

“If China hadn’t stopped [the novel coronavirus], the situation in the world would be even worse. They were on the front lines. They aren’t just fighting for China; they wanted to reduce the spread,” he added. “To blame China’s markets is not serious.”

https://m.jpost.com/International/Ambassador-to-China-talks-about-life-under-quarantine-in-Beijing-622406/amp#click=https://t.co/z1RveVK6ua

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to print (Opens in new window)
  • Click to email a link to a friend (Opens in new window)

Like this:

Like Loading...

  • Follow Blog via Email

    Enter your email address to follow this blog and receive notifications of new posts by email.

    Join 1,254 other subscribers
  • Recent Posts

    • Press Release for Five Bilingual BioMed e-Series January 29, 2023
    • 2022 FDA Drug Approval List, 2022 Biological Approvals and Approved Cellular and Gene Therapy Products January 17, 2023
    • Verily announced other organizational changes, 1/13/2023 January 16, 2023
    • Mission 4: Use of Systems Biology for Design of inhibitor of Galectins as Cancer Therapeutic – Strategy and Software December 13, 2022
    • Science Has A Systemic Problem, Not an Innovation Problem December 12, 2022
    • Chemistry Nobelist Carolyn Bertozzi’s years at UC Berkeley October 24, 2022
    • Technion #1 in Europe in Field of AI for 2nd Straight Year October 20, 2022
    • Endoglin Protein Interactome Profiling Identifies TRIM21 and Galectin-3 as New Binding Partners October 11, 2022
    • The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells October 11, 2022
    • Cancer Policy Related News from Washington DC and New NCI Appointments October 4, 2022
  • Archives

  • Categories

  • Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • 1 2012pharmaceutical
    • 1 Amandeep Kaur
    • 1 Aashir Awan, Phd
    • 1 Abhisar Anand
    • 1 Adina Hazan
    • 1 Alan F. Kaul, PharmD., MS, MBA, FCCP
    • 1 alexcrystal6
    • 1 anamikasarkar
    • 1 apreconasia
    • 1 aviralvatsa
    • 1 David Orchard-Webb, PhD
    • 1 danutdaagmailcom
    • 1 Demet Sag, Ph.D., CRA, GCP
    • 1 Dror Nir
    • 1 dsmolyar
    • 1 Ethan Coomber
    • 1 evelinacohn
    • 1 Gail S Thornton
    • 1 Irina Robu
    • 1 jayzmit48
    • 1 jdpmd
    • 1 jshertok
    • 1 kellyperlman
    • 1 Ed Kislauskis
    • 1 larryhbern
    • 1 Madison Davis
    • 1 marzankhan
    • 1 megbaker58
    • 1 ofermar2020
    • 1 Dr. Pati
    • 1 pkandala
    • 1 ritusaxena
    • 1 Rick Mandahl
    • 1 sjwilliamspa
    • 1 Srinivas Sriram
    • 1 stuartlpbi
    • 1 Dr. Sudipta Saha
    • 1 tildabarliya
    • 1 vaishnavee24
    • 1 zraviv06
    • 1 zs22

Powered by WordPress.com.

WPThemes.


%d bloggers like this: